



(51) International Patent Classification:

A61K 31/727 (2006.01) A61P 15/04 (2006.01)

A61K 38/11 (2006.01)

(21) International Application Number:

PCT/SE2013/050510

(22) International Filing Date:

7 May 2013 (07.05.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/644,036 8 May 2012 (08.05.2012) US

61/668,150 5 July 2012 (05.07.2012) US

(71) Applicant: DILAFOR AB [SE/SE]; Karolinska Institutet
Science Park, Retzius väg 8, S-171 65 Solna (SE).(72) Inventors: EKMAN-ORDEBERG, Gunvor; Ridvägen
18 A, S-182 39 Danderyd (SE). MALMSTRÖM, Anders;
Vapenkroken 19, S-226 47 Lund (SE).(74) Agent: BERGENSTRÄHLE & LINDVALL AB; Box
17704, S-118 93 Stockholm (SE).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: TREATMENT OF POSTPARTUM HAEMORRHAGE WITH CHEMICALLY MODIFIED HEPARIN OR HEPARAN
SULPHATE AND A UTEROTONIC AGENT




Figure 1c

(57) Abstract: The present invention refers to the use of certain sulfated glycosaminoglycans for treatment or prevention of post-partum haemorrhage. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with at least one uterotonic agent capable of promoting myometrial contractions of the uterus and thereby compress the vessels and cease the bleeding.